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Introduction: the correlation between primary antiphospholipid syndrome (APS) and 
  cardiovascular events is well known, but the correlation between APS and sudden death is not 
clear; it probably correlates with sympathetic alterations of the autonomic system.
Aim: To compare the autonomic nervous system (ANS) in a group of subjects suffering from 
APS against that of a control group with no cardiovascular risk factors, matched for age, sex, 
and body mass index.
Subjects and methods: An equal number (n = 31) of subjects with APS, and healthy controls, 
underwent autonomic evaluation: tilt test, deep breath, Valsalva maneuver, hand grip, lying-
to-standing, Stroop, and sweat tests.
Results: Cases in the APS group were positive for the tilt test, relating to changes in respiratory 
rate intervals, by comparison with controls. Results of other tests were also altered significantly 
in APS cases, by comparison with controls. (The sweat and Stroop tests were only performed 
in 14 cases). Autonomic disease did not correlate with age, sex, history of disease, arterial or 
venous thrombosis, or antibody positivity; only their coagulation parameters correlated with 
autonomic dysfunction.
Conclusion: Autonomic dysfunction in APS seems to correlate with coagulation parameters. 
APS patients should receive autonomic evaluation, to minimize the risks of fatal arrhythmias 
and sudden death.
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Introduction
Antiphospholipid syndrome (APS) is characterized by thrombosis, miscarriage, or 
thrombocythemia associated with positivity for lupus anticoagulant (LAC) or anti-
cardiolipin antibody tests.1,2 APS was initially described in patients with autoimmune 
disease, especially systemic lupus erythematosus (SLE), secondary to this disease.3 
The syndrome has also been described in subjects with no autoimmune disorder, where 
it is known as primary APS.4
Patients with rheumatic disease, even subclinically, often show cardiovascular and 
neural symptoms. The autonomic system is certainly affected, but reports are   conflicting, 
for various reasons. Autonomic symptoms vary, ranging from   gastrointestinal, to 
cardiovascular, to neural. Autonomic tests are not routinely performed. It is difficult 
to differentiate secondary cardiovascular effects, due to therapy, from the effects of 
the disease.
Research on autonomic dysfunction (AD) in autoimmune disease has identified 
alterations, with variability in the range of 24%–100%, depending on the method used.5 
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Cardiovascular autonomic dysfunction is most common in 
autoimmune diseases.6 The role of AD is debated. Attention 
has focused mainly on an “overreactivity of the sympathetic 
nervous system” point of view. This proposes that a central 
alteration may be involved. The role of the peripheral nervous 
system is uncertain.6,7
Our case–control study aimed to elucidate these contrast-
ing findings, and to clarify the correlation between APS and 
sudden death.
Subjects and methods
We examined 107 subjects with primary APS, diagnosed 
on the basis of the classic clinical and laboratory criteria 
(ie, a positive history of deep venous or arterial thrombosis 
or miscarriage, and antiphospholipid antibody positivity in 
two blood samples, obtained 2 months apart). All individuals 
were outpatients and were recruited during a period of 1 year 
(September 2008 to September 2009).
For each case, we recorded the patient’s clinical history, 
physical examination, electrocardiographic derivations 
(12-lead electrocardiogram [ECG]), and blood test findings, 
to assess cardiovascular risk factors (ie, smoking habits, 
hypertension, diabetes mellitus, hypercholesterolemia, and 
obesity) (Table 1), to check against exclusion criteria, and to 
identify any diseases correlated with atherosclerosis (ie, acute 
myocardial infarction, angina pectoris, transient ischemic 
attack, stroke, carotid endarterectomy, arterial vascular 
disease, or aortic aneurysm). We excluded subjects with 
autoimmune, neoplastic, thyroid, or hemorrhagic diseases, 
and those taking steroids or contraceptive pills.
Of the 107 cases observed, we excluded 76 because 
they had risk factors for atherosclerosis or previous clinical 
manifestations of atherosclerosis. The 31 remaining cases 
were paired with 31 healthy subjects, with no common risk 
factors for atherosclerosis, who were recruited at our clinic 
during the same observation period.
Antiphospholipid antibody assay
Antiphospholipid antibodies were measured in a 1:100 plasma 
dilution, using the Asserachrom® APA system (Diagnostica 
Stago, Paris, France). The dilutions used for   calibration were 
double-tested. Results were plotted on log–log graph paper, 
and the approximate plasma potential (UPL) levels were 
read from the calibration curve. Levels less than 10 UPL 
were considered negative. Levels between 11 and 15 were 
considered mildly positive; levels between 15 and 40 were 
considered moderately positive; and levels greater than 40 
were considered highly positive. The 10 UPL cut-off was 
approximately two standard deviations (SDs) higher than the 
mean level of 50 controls. Each test was duplicated.
The guidelines of the International Society on Thrombosis 
and Hemostasis Subcommittee for Standardization were fol-
lowed for LAC detection, as reported elsewhere.8,9
Tilting and autonomic tests
Subjects underwent cardiovascular autonomic nerve 
  function tests,10 performed in the following order: (1) deep 
breath, (2) Valsalva test, (3) isometric hand grip, (4) lying-
to-standing. In the deep breath test, a test for vagal heart 
rate control,11 the duration of the expiratory and inspiratory 
breaths was 5 seconds each, for a total of 40 seconds (four 
breathing cycles). The ratio of the longest to the shortest 
respiratory rate (RR) intervals was measured from the ECG 
for each breathing cycle. The mean of all four ratios was 
taken as the expiratory/inspiratory (E/I) ratio. Respiratory 
rate was measured using a chronograph.
For the Valsalva test, which measures both parasympa-
thetic and sympathetic function, subjects blew into a manom-
eter maintaining an intrathoracic pressure of 40 mmHg for 
15 seconds. The Valsalva ratio, of the shortest RR interval 
during the expiratory effort to the longest RR interval during 
the 20 seconds subsequent to strain, was calculated. The RR 
interval was measured from the ECG printout. Blood pres-
sure was assessed using an automated sphygmomanometer 
(TECNOMED, Udine, Italy).
In the isometric hand grip test, the subjects squeezed 
a dynamometer (TECNOMED) in their dominant hand 
for 3 minutes, using a force that corresponded to 30% of 
Table 1 Atherosclerotic risk factors
Risk factor
Smoking habits .5 cigarettes/day
hypertension Blood pressure .140/90 mmhg or therapy
Diabetes Fasting glycemia . 6.1 mMol/L or therapy
hypercholesterolemia Cholesterol . 5.2 mMol/L or therapy
Obesity BMI . 30
Abbreviation: BMI, body mass index.
Table 2 Characteristics of the population examined
Cases Controls
Sex 13 male, 18 female 13 male, 18 female
Age 47.4 ± 21 years 48.9 ± 25 years
BMI 23.6 ± 9.4 24.3 ± 10.7
heart rate 76.4 ± 13.4 69.8 ± 18.1
hypertension no no
Smoking no no
Diabetes no no
Abbreviation: BMI, body mass index.
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their maximal squeezing force. Heart rate and blood pres-
sure were measured at rest, before, and after gripping the 
dynamometer.
For the lying-to-standing test, subjects stood up suddenly, 
after lying quietly in a supine position for 5 minutes. Heart 
rate and blood pressure were measured at rest, then at 1, 3, 
5, and 7 minutes after standing up.
In the tilt test, the subject lay supine on an electric 
tilting table (TECNOMED). A restraining strap across the 
upper abdomen secured the subject to the table during the 
test, applying a negligible pressure to the surface of the 
body. Blood pressure and ECG recordings were obtained 
continuously throughout the test, which lasted 30 minutes. 
The test was considered to be positive only in the presence of 
symptoms fully reproducing a patient’s original pre-syncopal 
or syncopal symptoms, accompanied by arterial hypotension, 
bradycardia, or both.12,13
For the Stroop test, subjects were asked to read the names 
of seven colors, written on sheets of paper, as fast as they 
could, while lying down. The names of the colors were writ-
ten in colors different than those they named (eg, the word 
“green” was written in yellow). This test represents a mental 
stressor. In normal subjects, blood pressure and heart rate 
should rise by the end of the test.14
The quantitative sudomotor autonomic reflex test 
  measures the activity of small nerve fibers connected to 
sweat glands. The foot, leg, and forearm are typical test 
sites.15 A capsule was placed over the skin on the test site. 
A technician then stimulated a nearby sweat gland, by deliv-
ering a chemical substance through the skin, using a low-
Table 3 Autonomic tests in cases and controls
Autonomic test Cases Controls P
Tilt (rr ratio) 1.10 ± 0.09   1.14 ± 0.11 ,0.05
hand grip (mmhg) 5.75 ± 5.14 10.55 ± 12.73 ,0.05
Deep breath (E/I ratio) 1.15 ± 0.11   1.40 ± 0.15 ,0.05
Valsalva (valsalva ratio) 1.33 ± 0.19   1.74 ± 0.42 ,0.05
Lying-to-standing (mmhg) 0.55 ± 10.31 –9.81 ± 4.95 ,0.05
Abbreviations: rr, respiratory rate; E/I, expiratory/inspiratory.
Table 4 Correlation between sex and autonomic tests
Autonomic test Males Females P
Tilt (rr ratio) 1.09 ± 0.13 1.10 ± 0.03 ns
hand grip (mmhg) 4.85 ± 5.79 6.39 ± 4.69 ns
Deep breath (E/I ratio) 1.10 ± 0.11 1.19 ± 0.09 ns
Valsalva (valsalva ratio) 1.27 ± 0.25 1.37 ± 0.13 ns
Lying-to-standing (mmhg) 4.08 ± 13.93 –2.0 ± 5.86 ns
Abbreviations: RR, respiratory rate; E/I, expiratory/inspiratory; ns, not significant.
Table 5 Correlation between age and autonomic tests
Autonomic test Age ,50 years Age .50 years P
Tilt (rr ratio)   1.11 ± 0.03 1.09 ± 0.12 ns
hand grip (mmhg)   7.01 ± 5.67 4.40 ± 4.29 ns
Deep breath (E/I ratio)   1.19 ± 0.10 1.18 ± 0.11 ns
Valsalva (valsalva ratio)   1.38 ± 0.13 1.27 ± 0.24 ns
Lying-to-standing (mmhg) –1.63 ± 6.76 2.87 ± 12.96 ns
Abbreviations: RR, respiratory rate; E/I, expiratory/inspiratory; ns, not significant.
Table  6  Correlation  between  age  at  first  manifestation  and 
autonomic tests
Autonomic test Age at first  
manifestation  
,30 years
Age at first  
manifestation  
.30 years
P
Tilt (rr ratio)   1.10 ± 0.02   1.11 ± 0.03 ns
hand grip (mmhg)   4.34 ± 3.03   5.00 ± 5.37 ns
Deep breath (E/I ratio)   1.23 ± 0.07   1.21 ± 0.09 ns
Valsalva (valsalva ratio)   1.40 ± 0.12   1.34 ± 0.11 ns
Lying-to-standing (mmhg) –2.22 ± 6.98 –1.13 ± 6.03 ns
Abbreviations: RR, respiratory rate; E/I, expiratory/inspiratory; ns, not significant.
Table 7 Correlation between arterial or venous thrombosis at 
first manifestation and autonomic tests
Autonomic test Arterial events Venous events P
Tilt (rr ratio)   1.11 ± 0.03   1.10 ± 0.02 ns
hand grip (mmhg)   5.47 ± 4.44   3.02 ± 1.98 ns
Deep breath (E/I ratio)   1.18 ± 0.10   1.20 ± 0.10 ns
Valsalva (valsalva ratio)   1.37 ± 0.11   1.35 ± 0.10 ns
Lying-to-standing (mmhg) –1.33 ± 6.16 –1.40 ± 6.62 ns
Abbreviations: RR, respiratory rate; E/I, expiratory/inspiratory; ns, not significant.
Table 8 Correlation between history of disease and autonomic 
tests
Autonomic test History  
,15 years
History  
.15 years
P
Tilt (rr ratio)   1.11 ± 0.04   1.10 ± 0.02 ns
hand grip (mmhg)   5.42 ± 5.08   4.68 ± 3.26 ns
Deep breath (E/I ratio)   1.21 ± 0.08   1.16 ± 0.10 ns
Valsalva (valsalva ratio)   1.38 ± 0.15   1.36 ± 0.09 ns
Lying-to-standing (mmhg) –1.58 ± 7.41 –0.89 ± 6.13 ns
Abbreviations: RR, respiratory rate; E/I, expiratory/inspiratory; ns, not significant.
Table 9 Correlation between antibody positivity and autonomic 
(APA) tests
Autonomic test APA ,20 APA .20 P
Tilt (rr ratio)   1.11 ± 0.03   1.10 ± 0.02 ns
hand grip (mmhg)   5.42 ± 4.93   4.68 ± 3.41 ns
Deep breath (E/I ratio)   1.21 ± 0.11   1.16 ± 0.09 ns
Valsalva (valsalva ratio)   1.38 ± 0.11   1.36 ± 0.07 ns
Lying-to-standing (mmhg) –1.58 ± 6.56 –0.89 ± 5.86 ns
Abbreviations: RR, respiratory rate; E/I, expiratory/inspiratory; ns, not significant.
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voltage current. The amount of sweat under the capsule was 
measured repeatedly during the test. Computerized analysis of 
the results determined how well the sweat gland worked, and 
how well the nerves functioned to help the gland to release 
the sweat at a normal rate. (For this test, subjects should not 
have taken any medication that might interfere with perspi-
ration, such as tricyclic or other antidepressants, selective 
serotonin reuptake inhibitors, antihistamines, nitropatches, 
beta-blockers, diuretics, or angiotensin-converting enzyme 
inhibitors).15 Results were presented as mean ± standard 
deviation. A probability constant P , 0.05 was considered 
significant, and was calculated using Student’s t-test.
Results
There were 31 ASP cases (13 male, 18 female; mean age: 
47.4 ± 21 years), and 31 controls (13 male, 18 female; mean 
age: 48.9 ± 25 years) (Table 2). All of the autonomic test 
results were significantly altered in the ASP cases (Table 3). 
The sweat and Stroop tests were only conducted in seven 
cases and seven controls. Some cases showed significant 
alteration, but we did not perform statistical analysis for 
this small group.
After initial between-group comparisons, a within-group 
comparison was drawn, to correlate autonomic dysfunction 
with sex (Table 4), age (Table 5), first manifestation before/
after 30 years of age (Table 6), presence/absence of   arterial or 
venous thrombosis at first manifestation (Table 7),   history of 
disease (more/less than 15 years) (Table 8), antibody positiv-
ity (Table 9), and immunoglobulin M or G beta 2-glycopro-
tein I antibody positivity (Tables 10 and 11). None of these 
parameters correlated with autonomic dysfunction. However, 
we found a significant correlation between coagulation 
parameters and autonomic dysfunction (partial thromboplas-
tin time lupus antibody screening test: PTT-LA) (Figure 1).
Discussion
Numerous recent works have made it clear that connective 
tissue diseases correlate with cardiac rhythm disorders, which 
can be due to endocarditis, myocarditis, or pericarditis, or 
to coronary thrombotic events or autonomic dysfunction.16,17 
A recent study showed that autonomic dysfunction is com-
mon in autoimmune diseases,18,19 and that neuropsychiatric 
alterations are commonly reported in patients with rheumatic 
diseases such as SLE,20 though researchers were unable to say 
whether the neural involvement was primary or secondary 
to the connective disorders.19
Our work confirms these autonomic alterations, par-
ticularly in APS, in a sizable sample of cases. The numbers 
of cases considered in other works were very limited, and 
patients often had other associated diseases, such as SLE.21 
Our findings seem important because we matched our cases 
with control subjects, who had no atherosclerotic lesions that 
might alter the results. Our study also aimed to determine 
whether autoimmune alterations were the cause of the auto-
nomic disease, or a secondary effect of it.
Our results seem to indicate that thrombophilic states may 
contribute to neural alterations, probably connected to the 
cerebrovascular diseases of this syndrome.22 If further stud-
ies confirm our findings, we might argue that antithrombotic 
therapy could reduce the possibility of autonomic neural 
involvement, and thus prevent conduction disorders. This is 
an indirect, but promising working assumption.
Table 10 Correlation between cases with/without β2IgM positivity
Tilt  
(RR ratio)
Hand grip  
(mmHg)
Deep breath  
(E/I ratio)
Valsalva  
(valsalva ratio)
Lying-to-standing 
(mmHg)
β2IgM+ 1.03 ± 0.14 10.82 ± 3.93 1.24 ± 0.11 1.16 ± 0.18 2.20 ± 11.23
β2IgM- 1.12 ± 0.07 13.60 ± 5.59 1.37 ± 0.44 1.37 ± 0.44 –1.20 ± 5.54
P ns ns ns ns ns
Abbreviations: rr, respiratory rate; E/I, expiratory/inspiratory; β2IgM, beta 2-immunoglobulin M glycoprotein antibody test; ns, not significant.
Table 11 Correlation between cases with/without β2IgG positivity (.20 U/mL)
Tilt  
(RR ratio)
Hand grip  
(mmHg)
Deep breath  
(E/I ratio)
Valsalva  
(valsalva ratio)
Lying-to-standing 
(mmHg)
β2IgG+ 1.04 ± 0.13   6.02 ± 4.03 1.12 ± 0.11 1.31 ± 0.19 2.33 ± 5.27
β2IgG- 1.12 ± 0.06 12.33 ± 5.89 1.38 ± 0.22 1.41 ± 0.40 –8.7 ± 5.13
P ns ns ns ns ns
Abbreviations: rr, respiratory rate; E/I, expiratory/inspiratory; β2IgG, beta 2-immunoglobulin G glycoprotein antibody test; ns, not significant.
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Conclusions
Our results show that autonomic dysfunction is associated 
with primary antiphospholipid syndrome, and correlates 
closely with thrombophilic states. Further confirmation of 
this important finding may lead to new therapeutic strategies 
for treating autonomic dysfunction.
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